• Explore /
  • Poster
  • / KEYNOTE-240: Randomized phase III study of pembrolizumab versus best supportive care for second-line advanced hepatocellular carcinoma.

KEYNOTE-240: Randomized phase III study of pembrolizumab versus best supportive care for second-line advanced hepatocellular carcinoma.

Abstract Poster

Authors

null

Richard S. Finn

University of California, Los Angeles, Los Angeles, CA

Richard S. Finn , Stephen L. Chan , Andrew X. Zhu , Jennifer J. Knox , Ann-Lii Cheng , Abby B. Siegel , Oliver Bautista , Pat Watson , Masatoshi Kudo

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 Gastrointestinal Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Track

Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Sub Track

Multidisciplinary Treatment

Clinical Trial Registration Number

NCT02702401

Citation

J Clin Oncol 35, 2017 (suppl 4S; abstract TPS503)

DOI

10.1200/JCO.2017.35.4_suppl.TPS503

Abstract #

TPS503

Poster Bd #

N21

Abstract Disclosures

Similar Posters

First Author: Richard S. Finn

Poster

2017 Gastrointestinal Cancers Symposium

KEYNOTE-224: Phase II study of pembrolizumab in patients with previously treated advanced hepatocellular carcinoma.

KEYNOTE-224: Phase II study of pembrolizumab in patients with previously treated advanced hepatocellular carcinoma.

First Author: Andrew X. Zhu

First Author: Shukui Qin

First Author: Shukui Qin